These Analysts Slash Their Forecasts On Rocket Pharmaceuticals

benzinga.com/25/05/45641790/these-analysts-slash-their-forecasts-on-rocket-pharmaceuticals

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) announced an update Tuesday related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles), skeletal myopathy…

This story appeared on benzinga.com, 2025-05-28 12:22:19.
The Entire Business World on a Single Page. Free to Use →